INDIA ICMR Rejects Merck’s Molnupiravir as Antiviral for COVID-19—Not Effective & Material Safety Concerns

Although Merck went down what many critics, including this platform, called a twisted, curvy path to get Molnupiravir commercialized—including signed deals with multiple pharmaceutical producers in India—it’s looking bleak for the antiviral therapy’s prospects in India. Why? As TrialSite reported, India’s apex medical research organization called Indian Council of Medical Research (ICMR) declared that despite the approval of the drug by this nation’s drug regulatory body—the Drugs Controller General of India (DCGI)—the top doctor for ICMR, Balram Bhargava recently stated publicly that his influential group had “major safety concerns” associated with molnupiravir. Now, the Times of India and several other media in the world’s second-most populous nation report that an ICRM national task force focused on COVID-19 will opt to not recommend the antiviral drug molnupiravir in their clinical management protocol for COVID-19. U.S. taxpayers subsidized this product, with $356 million to support research and $1.2 billion in guaranteed procurement contracts.

Safety Concerns

Even though molnupiravir has been authorized for use on an emergency basis in the United States, Europe, and oth...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee